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Abstract
Objective—to examine changes in the prevalence of antipsychotic medication use and the
characteristics of antipsychotic users in the US population.
Methods—We use data from the Medical Expenditure Panel Survey from 1996/97 and 2004/05 to
examine the rate of first and second-generation antipsychotic medication use and changes in the
characteristics of users of all ages. We examine trends in the level of use by antipsychotic users both
in terms of daily dose units and number of prescriptions.
Results—The rate of antipsychotic use has increased substantially between 1996/97 and 2004/05,
but the average dose measured both by daily dose units and number of prescriptions has remained
constant. The rapid diffusion of antipsychotic medications occurred not among individuals with
schizophrenia, but rather includes substantial growth in off-label users and newer on-label conditions.
Demographic, financial, and insurance characteristics of users have remained fairly constant, with
few exceptions. The average age of antipsychotic users has declined from 1996–2005 as more
children are using these medications. The gender, racial, ethnic, and insurance composition of users
has been fairly stable over time, however.
Conclusions—The rapid diffusion of second-generation antipsychotic medications was achieved
by large increases in the rate of use in certain subpopulations, most notably children. Increasing
understanding of the marginal efficacy and side-effect risks of newer and more expensive
antipsychotic agents, even when prescribed as indicated, suggests that the dramatic increase in use
warrants careful attention.
Introduction
Second-generation antipsychotics have diffused rapidly among antipsychotic medication users
and have generally been regarded as a first-line treatment for schizophrenia (1–4). Additional
FDA indications for use in bipolar and significant levels of off-label use and use in children
have increased the rate of antipsychotic medication use (5—8). Antipsychotics have greater
off-label use than do many other therapeutic classes and these uses may not be well-supported
by scientific evidence (9).
While spending on psychotropic medications is increasing at a higher annual rate than is
spending on other medications (17.1% vs. 12.1%) (10–11). psychotropic drugs may still be
underused in mental health care (12) due to barriers to treatment such as cost and stigma.
Increases in antipsychotic medication use are justifiable if the population with conditions
appropriately treated with antipsychotics, such as schizophrenia and bipolar disorder are under-
treated, and if antipsychotic medication treatment is cost-effective (13) compared with other
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alternatives. This implies that second-generation antipsychotics may not have to “pay for
themselves” in terms of providing an offset in lower total health care costs (14), but should
provide greater benefits per dollar spent than older less expensive antipsychotics or other
treatments.
Although there is significant variation in the benefit from drug products across individuals
(15), in theory drugs that provide greater value should diffuse much more quickly than other
drugs. However, this is not always the case. Treatment decisions are made under a veil of
uncertainty and market imperfections, and are subject to a host of influences on prescribers:
prescribers are never sure a priori which products will work best for any individual and
information on side effects is often recognized over time (as has been the case with significant
product withdrawals such as Vioxx). Diffusion of specific medications into treatment can be
improved with a larger evidence base (16) on which to examine whether the growth of particular
products is indeed rational.
The CATIE trial was an effort to examine whether the rapid diffusion of second-generation
antipsychotics is well informed by examining the effectiveness and tolerability of four second
and a single proxy for first-generation antipsychotics (17). The CATIE cost-effectiveness
analysis (1) found that while the outcomes expressed in Quality-Adjusted Life Year units were
similar across all five drugs, the total health care costs for those randomized to the first-
generation antipsychotic, perphenazine, were substantially lower than for the second-
generation antipsychotics. A recent study in the UK comparing first versus second-generation
antipsychotics in a sample of previously-treated individuals with schizophrenia found lower
costs and better outcomes in the older medications (18). These results may indicate that the
widespread use of second-generation antipsychotics over first-generation alternatives may not
be the best use of limited resources.
While the diffusion of second-generation antipsychotics has been described in the literature
(2,3,12), the method by which these gains have been achieved has not been explored. There
are two primary means of achieving market growth for pharmaceutical products: increases in
the number of medication users or increases in dose per user; these two mechanisms are not
mutually exclusive. It is unknown which is driving the current growth in antipsychotic
medications, although one recent study using MEPS data notes that just over a third of the
increase in the larger class of psychotropic medication was due to new users whereas two-
thirds of the increase was due to greater spending per user (6). In addition, much of our
knowledge about antipsychotic medication use comes from Medicaid populations (2,19) with
little information available on trends in the use of antipsychotics from privately insured and
uninsured populations.
This manuscript seeks to fill these gaps in the literature by examining the prevalence of
antipsychotic medication use in the general population and the characteristics of antipsychotic
users, including the rate of second-generation antipsychotic use and the level of use per user.
Methods
We use data from the Medical Expenditure Panel Survey (MEPS) from 1996 to 2005 to examine
the characteristics of users in each time period as well as the rate of use in key subpopulations.
The MEPS is a rich overlapping panel dataset with a randomly selected annual sample of
approximately 23,000–35,000 non-institutionalized US civilians and detailed information on
health care services used in each survey year, insurance coverage, and expenditures by source
(20). Response rates ranged from 60–70% for the annual cohorts examined here and survey
weights were adjusted for non-response (21), reducing selection bias. Clinical and expenditure
Domino and Swartz Page 2













information is available in MEPS both from household respondents and from provider and
pharmacy follow-back surveys. Both children and adults were included in the analysis.
The study years were selected by necessity from those available in the MEPS: 1996 is the
earliest year available and 2005 is the most recent as of the writing of this manuscript. Because
of the relatively small sample size of antipsychotic users, we pool adjacent years for this
analysis and compare 1996–1997 to 2004–2005 (22–23). Thus means and proportions
represent averages across each two-year period. 1996/97 is early in the diffusion path of second
generation agents and therefore an interesting comparator to the 2004/05 period when these
agents were widely used. Clozapine was approved by the FDA for the treatment of
schizophrenia in 1989, Risperidone in 1993, Olanzapine in 1996, and Quetipine in 1997; other
second generation agents and newer approved indications for existing agents followed in the
2000s. Because relatively small subsamples remain for some analyses, we indicate cell sizes
relying on unweighted samples of less than 100 respondents (23) and urge caution in
interpreting estimates based on small cell sizes. We retain the estimates in these cells for
descriptive purposes only and do not conduct statistical tests against cells with fewer than 50
observations.
The prevalence of antipsychotic medication use was estimated from the MEPS prescription
drug files in each year. Antipsychotic medications were identified via the Multum Lexicon
categories appended by MEPS staff to each prescription (24). Modifications to this system
were made, for example, excluding lithium, chlordiazapoxide, and prochlorperazine
prescriptions from the Multum antipsychotic category.
Prescriptions were converted to defined daily dose (DDD) units in order to calculate quantity
of use across formulations. The DDD system is promoted by the World Health Organization
(http://www.whocc.no/atcddd/) and allows the quantity of medications received to be
expressed in terms of the number of days’ supply of medication received on a standardized
maintenance dose (Appendix Table 1); these standardized doses were within the ranges
specified in the CATIE protocol (17). The conversion to DDD was applied to all antipsychotic
prescriptions regardless of target condition or age of the patient. While the maintenance dose
may not be the appropriate dose of medication for some antipsychotic users (e.g., those
initiating therapy, children and elderly patients, off-label users), it does provide a way of
examining average dosing over time across antipsychotic regimens. Increases in average DDDs
per user may be due to actual dose increases or to polypharmacy since doses are added up
across formulations for each user. In contrast, decreases in average DDDs may be due to
expansions to populations which may have lower target dosing (children, elderly) as well as
increases in off-label use.
Other characteristics reported were obtained from the MEPS household survey (20) for each
year for antipsychotic users only. The reported characteristics focus on exogenous factors that
describe the population of antipsychotic users so as to avoid providing outcome data that may
be influenced by choice of antipsychotic agent. We do, however, report antipsychotic and total
health care expenditures and insurance variables, noting that these measures may be a function
of treatment selection. Other characteristics examined include age, especially use in children
(under age 18), the elderly (age 65 and over), payor status, employment status, and the number
of other medication classes used. All spending estimates are presented in 2005 dollars, having
been deflated by the GDP deflator. Complex sampling weights and variances appropriate for
the pooled analysis (22) were used to obtain nationally representative estimates; differences
across years were examined with t- and chi-square tests. All analyses were conducted in Stata
10 using svy commands to adjust for the complex survey design of MEPS. Linearized standard
errors are reported in the tables.
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The issue of off-label prescribing of antipsychotics is only partially addressed in the present
analysis. Medical conditions available in the Household Component of the MEPS are by self-
report only and are available in the public release version of MEPS as collapsed 3-digit ICD-9
codes to protect respondent confidentiality. Conditions are reported in the MEPS both in a
separate section on medical conditions and injuries and from all reports of health services and
medications used. We identify individuals who self-report any condition in the ICD-9
categories for on-label use, namely schizophrenic disorders (295) or bipolar disorder, which
is a subset of the larger ICD-9 category of affective disorders (296). Because unipolar major
depression is also classified in 296, we are unable to separate off-label use in depression from
on-label use in bipolar disorder due to the unavailability of the fourth digit of the ICD-9 code
and therefore will over-count on-label use. Our use of the terms on and off-label relies on these
collapsed 3-digit self-reported medical conditions and should be interpreted accordingly. We
also examine changes in other reported off-label uses of antipsychotics (25) for anxiety-
spectrum disorders (300) including obsessive-compulsive disorders; this category does not
include other common anxiety disorders. We are unable to evaluate other off-label conditions
that have been noted in the literature due to inadequate sample sizes in all years. Because of
the potential for comorbidity among these three conditions, we indicate 296-affective disorders
only among those without reported schizophrenia, and anxiety-spectrum disorders only among
those without either schizophrenia or 296-affective disorders. The reliance on self-reported
conditions will potentially undercount each of these related conditions, while the use of
collapsed 3-digit ICD-9 categories will overcount the more narrowly identified disease areas;
the net effect is ambiguous. Our use of code groupings is not all-inclusive and was intended
to identify major diagnostic categories for which antipsychotics might be used. There is no
reason to believe that the population rate of under-reporting or of actual disease prevalence has
changed over the study period (26).
Finally, we examine whether the characteristics that predict antipsychotic use and second-
generation use among antipsychotic users have changed over time through a weighted linear
probability model regression analysis, using demographics, insurance status, year indicators,
and interactions of these factors and year indicators. We run this regression separately for adults
and children, and adjust standard errors for heteroskedasticity and clustering.
Results
Second-generation antipsychotics have diffused rapidly between 1996–2005. In 2004/05,
1.17% of the non-institutionalized US population filled prescriptions for antipsychotic
medications, up from 0.72% in 1996/97 (p<0.01; Table 1).
The population prevalence of second-generation use increased almost 7-fold in eight years,
with 0.15% of the population using second-generation antipsychotics in 1996/97 to 1.06% in
2004/05. The use of first-generation agents dropped during this period from 0.60% to 0.15%
of the US population.
While the size of the antipsychotic market has increased, the characteristics of users have
remained fairly constant, with some exceptions. Notably, the average age of antipsychotic users
has declined, from 49 years of age to 43 (p<0.01). This age reduction resulted from a shift in
the distribution of users from elderly users towards children (Figure 1). The percentage of the
user population accounted for by children has doubled for this 8-year period, from 7% to 15%
of all users (p<0.01). This increase in antipsychotic use by children can also be seen by a more
than tripling of the rate of antipsychotic use from 0.2% to 0.7% in children (Figure 2). Elderly
users have declined from 23% of all users to 14%, but experienced no change in the rate of
use. The rate of use in non-elderly adults also increased from 0.8% to 1.3%, although they
remained a constant 67–69% of antipsychotic users. The gender, racial, and ethnic composition
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of users has been fairly stable over time, with women comparison a slight majority of users
(55%) and whites accounting for 76–81% of users.
The insurance status of antipsychotic users also remained fairly constant over this time period.
While Medicaid is thought to dominate payments in this market, only 46–47% of outpatient
antipsychotic users had Medicaid coverage in the year. Antipsychotic users were almost as
likely to be covered by private insurance, with 41–42% of the population of users covered by
private plans during the calendar year. The labor market participation of individuals remained
fairly constant at 30–32% and the percent of users with household incomes less than 200% of
the poverty level at 55% to 58%.
The data show a remarkable shift in the related on and off-label diagnoses for antipsychotic
users (Figure 1 & Figure 3). Across years, 14–19% of users reported having a schizophrenia
disorder and those with this disorder reported a stable level of antipsychotic use (86–90%).
However, the percent of users with a 296-affective disorder without comorbid schizophrenia
increased substantially from 8% of all users to 22% of all users (p<0.01) and the rate of use
for individuals in this category increased from 18% to 35%. The reported prevalence of anxiety-
spectrum disorders without on-label comorbidities among antipsychotic users was constant at
18%–19%, and the rate of antipsychotic use in this category remained constant at 5%. The self-
reported prevalence of anxiety spectrum in the ICD-9 code class 300 only in the full U.S.
population doubled from 2.4% to 4.8% (p<0.01).
The average dosing of antipsychotics among users, expressed in daily dose units, remained
fairly constant across this time period, ranging from 144 daily doses per user in 1996/97 to 115
daily doses per user in 2004/05. The average number of antipsychotic prescriptions per user
remained constant, at about 7 per year. The average antipsychotic user received a greater
number of other medications, increasing from 3.3 in 1996/97 to 4.1 in 2004/05 (p<0.05).
While spending on antipsychotic medication in non-institutional settings prior to applicable
discounts has clearly increased over this period, starting as a $1.1 billion market in 1996/97
(in 2004–05 dollars) and currently over $4.6 billion per year in 2004/05, the payor composition
has remained stable. Individuals and their families are the largest source of payments for
antipsychotics, paying for 37–41% of the total market whereas Medicaid paid for just over a
third (35–36%). Private insurance payments accounted for about one-fifth (18–22%) of the
outpatient antipsychotic market.
We find no difference across racial and ethnic categories in the probability of using
antipsychotic medication after controlling for covariates among adults. Adults with self-
reported schizophrenia, 296-affective disorders, or anxiety-spectrum disorders were more
likely to use antipsychotics than were those without these conditions. Having a 296-affective
disorder without comorbid schizophrenia was 14 percentage-points more likely to lead to an
antipsychotic prescription in 2004/05 than in 1996/97 (p=0.01). No other condition or
characteristic was associated with greater use in 2004/05. Among children, girls, African
Americans, and Latinos were less likely to use antipsychotics in all study years (p<0.05), but
the differences were small. Both schizophrenia and anxiety spectrum disorders and not 296-
affective disorders increased the probability of childhood antipsychotic use in 2004/05 over
1996/97.
Individuals receiving antipsychotic medications were 68 percentage-points more likely to
receive a second-generation antipsychotic in 2004/05 than in 1996/97. Respondents with
income under 200% of the Federal poverty level were more likely to receive a newer
antipsychotic in 1996/97 than those with higher income, controlling for self-reported
conditions and other covariates, but less likely to receive an atypical antipsychotic in 2004/05.
This suggests that low-income patients (or their doctors) were early adopters and that the other
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users caught up in 2004/5. No other differences in predictors of second-generation use were
significant at the 95% level between sample periods (full results available from author by
request).
Discussion and Conclusions
Despite a fairly constant rate of individuals in the US with mental illness (26), there have been
notable shifts in the population of non-institutionalized US civilians using antipsychotic
medications. We found substantial increases in the number of individuals filling antipsychotic
prescriptions in the general US population, but no increase in the level of use among
antipsychotic users since the mid-1990s, measured by both daily dose units and by the number
of prescriptions.
The relatively constant rate of use among individuals who self-report schizophrenia indicates
that the rapid diffusion of second-generation antipsychotics was not associated with a greater
rate of treatment in this population. Rates of antipsychotic use among those reporting
schizophrenia were stable across years and no difference was found in reporting rates across
years (p=0.685), although rates are lower than in other studies (27). The expansion of the
antipsychotic market, instead, occurred among other disease categories, such as those with
296-affective disorders.
The fact that the increased use of second-generation antipsychotics was not accompanied by
a higher dosing is surprising and may mask several competing trends. Second-generation
antipsychotics were originally touted as less-toxic alternatives to first-generation agents (28–
30), which, if true, should have increased the level of use. However, during the sample period,
more information became available on the negative health effects of some second-generation
antipsychotic medications, leading the FDA in 2003 to issue a warning regarding the risk of
hyperglycemia and diabetes mellitus based on several studies which were published during our
study period (31). In addition, the remarkable increases in the rates of use for off-label
conditions and use in children (5,19,25,32,33) may lead to lower dosing.
The data examined here largely predate the CATIE results, but the question remains: why did
second-generation antipsychotics diffuse so rapidly? The answer is complex, and is likely a
function of factors not examined here, such as provider and patient expectations and
preferences, drug company marketing effects (12,13) and the dominance of industry-funded
trials in the early second-generation antipsychotic efficacy literature (28–30). In addition,
clinical and malpractice risk concerns about the higher rate of tardive dyskinesia associated
with first-generation vs. second-generation antipsychotics also drove diffusion. The trends here
mimic the rapid diffusion of the newer antidepressant medication, especially among children
(34).
It is clear that the appropriate use of antipsychotic medications improve the quality of life for
people with schizophrenia and related disorders (12), but recent evidence from the CATIE and
other studies (35–37) has brought into question whether the more expensive second-generation
antipsychotics are really a better use of resources compared to first-generation antipsychotics.
The lower risk of tardive dyskinesia may be one area in which second-generation antipsychotics
have an advantage of first-generation antipsychotics, although this is recently been questioned
(35) and may be overshadowed by the greater risk of diabetes, obesity, and other related
conditions (4); many of these risks were disclosed during our study period (38). Second-
generation antipsychotics will only increase in use as they begin to come off patent, opening
the market for less expensive generic substitutes, and triggering a wave of less restrictive
policies, especially in Medicaid and Medicare Part D formularies.
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The greater use of antipsychotics in pediatric populations is consistent with other work (5) and
is an important policy issue. Antipsychotics are used in childhood disorders other than
schizophrenia, such as autism and disruptive behavior disorders, but little is known about their
efficacy and long-term effects and differences in the types and intensity of side effects have
been noted (5,7,8).
A number of limitations should be noted for this analysis. The MEPS does not survey
institutionalized individuals, who may have different patterns of antipsychotic use. Therefore
the size of the full antipsychotic market and specifically the amount paid by Medicaid are
understated in this study. Several of the cells for 1996/97 are based on fewer than 100
observations and may be less reliable; they are presented for descriptive purposes only but this
in itself is a telling indicator of the rates of use in these subpopulations in the earlier time period.
The self-reported medical conditions are not as accurate as clinician diagnoses and clearly
understate the prevalence of disease in the population. For example, Wu and colleagues (39)
estimate a 12-month prevalence of schizophrenia of 0.51% using a variety of claims data
sources, whereas the MEPS reported prevalence is 0.16–0.18%. In addition, the on-label rates
reported here, ranging from 27.5% in 1996/97 to 35.8% in 2004/5, are likely too low, although
the inclusion of all 296 affective disorders as on-label underestimates off-label use. Other rates
reported in the literature use claims diagnoses and are slightly higher, ranging from 36% in
Georgia Medicaid in 2001 (39) to 44% of second-generation antipsychotic use in 2004 (40);
Radley and colleagues report an off-label rate of 31% for the broader psychotropic category
(9). The conversion to daily dose units are based on current dosing guidelines and do not vary
over the study period. We do, however, find consistent results whether we look at the annual
number of daily doses or the number of antipsychotic prescriptions.
While literature from the CATIE study has increased the knowledge base surrounding the use
of antipsychotic medications, there are a number of issues that remain to be examined. As with
most clinical trials, the population studied in CATIE may not resemble the full spectrum of
medication users (13). In particular, users with schizophrenia and Alzheimer’s represent a small
fraction (<20%) of all antipsychotic users. Further information on the cost-effectiveness of
antipsychotic use in these non-traditional but increasingly common categories of use would
inform the diffusion process. Finally, while CATIE itself may affect antipsychotic diffusion,
early results in a privately insured population found no effect of CATIE on antipsychotic use
(41). Inferences from CATIE were complicated by the introduction of Medicare Part D shortly
after the initial CATIE results were released; Part D itself will also substantially affect the use
of antipsychotic medications as Medicaid funding and associated restrictions on medication
use for dually-eligible Medicare beneficiaries shifted to the Medicare program (42). If
prescribers become willing to return to the earlier technology of first-generation antipsychotics
as the CATIE message is repeated, we may see a substantially different diffusion process over
the next decade.
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FPL=Federal Poverty Level. In 2006–7, multiple racial categories were allowed; in these years
white and black both indicate no other categories were recorded. Affective disorder includes
only those disorders coded in the ICD-9 category of 296 and excludes individuals with
comorbid schizophrenia. Anxiety spectrum disorders exclude individuals with comorbid
schizophrenia or 296-affective disorders. Some cell sizes for 1996/97 are smaller than 100
observations as noted in Appendix Table 1. * chi-square tests for discrete variables were
significant at p<0.01. + comparisons are descriptive only due to small cell sizes in 1996/97.
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Figure 2. Prevalence of Antipsychotic Use by Characteristics
FPL=Federal Poverty Level. In 2006–7, multiple racial categories were allowed; in these years
white and black both indicate no other categories were recorded. Some cell sizes for 1996/97
are smaller than 100 observations as noted in Appendix Table 2. * chi-square tests for discrete
variables were significant at p<0.01. + comparisons are descriptive only due to small cell sizes
in 1996/97.
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Figure 3. Prevalence of Antipsychotic Use by Self-reported Psychiatric Condition
Note: conditions are reported by survey respondents and are not clinical diagnoses. Affective
disorders include only those in the 296 ICD-9 category and exclude those individuals who
report schizophrenia (295) in the same survey year. Similarly, anxiety spectrum disorders
include only conditions in the ICD-9 category of 300 and exclude those individuals who report
either schizophrenia or 296 affective disorders.
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Table 1
US Population characteristics on antipsychotic users
Variable 1996–97 2004–5
Percent Linearized Standard Error Percent Linearized Standard Error
Percent of US population
with any antipsychotic use
0.72% ** 0.06 1.17% 0.07
Percent with any use of
first-generation
antipsychotics
0.60% ** 0.05 0.15% 0.02
Percent with any use of
second-generation
antipsychotics
0.15% ** 0.02 1.06% 0.06
Source: Author’s calculations using the MEPS data (20); population rates have not been adjusted for covariates;
*
chi-square test significant at p<0.05
**
p<0.01
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Table 2
Characteristics of Antipsychotic use and spending (weighted)
Variable 1996–97 2004–05





defined daily dose units
for users














    Medicaid 3.0 0.4 2.8 0.2
    Private insurance 1.3 0.2 1.4 0.1





$550** 56 $1344 93
Mean total health care
expenditures




(millions of 2005 dollars)





    Medicaid 36.2% 3.3 34.9% 2.3
    private insurance 18.3% 2.5 21.8% 1.9







Source: Author’s calculations using the MEPS data (20)
*
chi-square tests for discrete variables or t-tests for continuous variables were significant at p<0.05
**
p<0.01
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Appendix Table 1
DDD for antipsychotics mentioned in the MEPS data (source: WHO)
ATC Drug Name Daily Dose
N05AA01 Chlorpromazine 300 mg
N05AB02 Fluphenazine 10 mg
N05AB03 Perphenazine 30 mg
N05AB06 Trifluoperazine 20 mg
N05AC02 Thioridazine 300 mg
N05AC03 Mesoridazine 200 mg
N05AD01 Haloperidol 8 mg
N05AE02 Molindone 50 mg
N05AE04 Ziprasidone 80 mg
N05AF04 Thiothixene 30 mg
N05AH01 Loxapine 100 mg
N05AH02 Clozapine 300 mg
N05AH03 Olanzapine 10 mg
N05AH04 Quetiapine 400 mg
N05AX08 Risperidone 5 mg
N05AX12 Aripiprazole 15 mg
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Appendix Table 2
Characteristics of Antipsychotic users and rates of antipsychotic use
Variable 1996–97 2004–05
Mean/percent Linearized Standard Error Mean/percent Linearized Standard Error
Demographics, Income, and Insurance characteristics
Age 48.7 ** 1.6 42.7 1.1
Age groups
Children (under 18)
  Percent of Antipsychotic
Users
6.9%++ 1.7 14.7% 1.6
  Rate of Antipsychotic Use 0.2%++ 0.05 0.7% 0.08
[n=39]
Non-elderly adults (18–64)
   Percent of Antipsychotic
Users
66.5% 3.4 69.4% 2.5
  Rate of Antipsychotic Use 0.8%** 0.07 1.3% 0.09
Elderly (65 and over)
  Percent of Antipsychotic
Users
22.9%* 3.3 14.2% 1.9
  Rate of Antipsychotic Use 1.4% 0.2 1.4% 0.2
[n=85]
Female
  Percent of Antipsychotic
Users
54.7% 3.5 54.6% 2.5
  Rate of Antipsychotic Use 0.8%** 0.08 1.3% 0.08
Hispanic Ethnicity
  Percent of Antipsychotic
Users
7.9% 1.7 10.9% 1.7




  Percent of Antipsychotic
Users
80.5% 2.7 75.6% 2.5
  Rate of Antipsychotic Use 0.7%** 0.06 1.1% 0.07
Black
  Percent of Antipsychotic
Users
18.4% 2.7 16.5% 2.0
  Rate of Antipsychotic Use 1.0%* 0.1 1.5% 0.2
[n=90]
Insurance Status
  Any private insurance
during Year
  Percent of Antipsychotic
Users
41.3% 3.8 42.2% 2.3
  Rate of Antipsychotic Use 0.4** 0.05 0.7% 0.06
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Variable 1996–97 2004–05
  Any Medicare coverage
during Year
  Percent of Antipsychotic
Users
42.6% 3.7 35.6% 2.7
  Rate of Antipsychotic Use 2.2% 0.3 2.9% 0.3
  Any Medicaid coverage
during Year
  Percent of Antipsychotic
Users
46.9% 3.9 45.6% 2.6
  Rate of Antipsychotic Use 2.7% 0.3 3.4% 0.2
Family Income less than
200% of the Federal Poverty
Level
  Percent of Antipsychotic
Users
58.1% 3.4 54.6% 2.6
  Rate of Antipsychotic Use 1.3%** 0.1 2.0% 0.1
Percent with labor market
participation in year
  Percent of Antipsychotic
Users
29.8% 3.1 31.5% 2.6
  Rate of Antipsychotic Use 0.4%** 0.05 0.7% 0.07
Selected On- and Off-Label conditions reported in year
Potential on-label users, self-reported diagnosis in year
  Schizophrenia
  Percent of Antipsychotic
Users
19.3% 2.9 14.1% 1.9
  Rate of Antipsychotic Use 85.9% 4.6 90.0% 4.3
[n=80]
  296 Affective disorders
(without schizophrenia)
  Percent of Antipsychotic
Users
8.2%++ 1.9 21.7% 2.1
  Rate of Antipsychotic Use 18.1%++ 4.1 34.5% 3.0
[n=38]
Potential off-label users, self-reported diagnosis in year
  Anxiety disorders (without
296 affective disorders or
schizophrenia)
  Percent of Antipsychotic
Users
17.9% 2.2 18.8% 2.0








Source: Author’s calculations using the MEPS data (20). The first line of each cell gives the percent of each characteristics among antispsychotic users
(column percentages), whereas the rates of antipsychotic use in each subpopulation (row percentages) are given in parentheses. Cell sizes of less than 100
unweighted observations are indicated in square brackets.
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+
In 2006–7, multiple racial categories were allowed; in these years white and black both indicate no other categories were recorded.
++
formal statistical tests are not reported due to small cell sizes, estimates should be considered descriptive only;
*
chi-square tests for discrete variables or t-tests for continuous variables were significant at p<0.05
**
p<0.01
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